Nuclear expression of BCL10 or nuclear factor kappa B helps predict

*Helicobacter pylori*-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21)

Kun-Huei Yeh,1,2,4,10 Sung-Hsin Kuo,1,4,5 Li-Tzong Chen,7,8 Tsui-Lien Mao,3 Shin-Lian Doong,6 Ming-Shiang Wu,2 Hui-Chen Hsu,1,4 Yi-Shin Tzeng,1,4 Chi-Long Chen,8 Jaw-Town Lin,2 Ann-Lii Cheng1,2,4,7

Departments of 1Oncology, 2Internal Medicine, and 3Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

4Cancer Research Center, 5Graduate Institute of Clinical Medicine, and 6Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan

7Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan

8Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

9Department of Pathology, Taipei Medical University, Taipei, Taiwan

10Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan
**Running title:** BCL10 and NF-κB in low-grade gastric MALT lymphomas.

**Keywords:** MALT lymphoma, *H pylori*, BCL10, NF-κB, API2-MALT1

**Scientific section heading:** NEOPLASIA

**Research grant support:** This study was supported by research grants NSC91-3112-B-002-009, NSC92-3112-B-002-027, and NSC93-3112-B-002-007 from the National Science Council, NHRI-CN-CA9201S (92A084, and 93A059) from the National Health Research Institutes, and NTUH 93-N012, NTUH 94S155 from National Taiwan University Hospital, Taiwan.

**Text word count:** 4239

Address reprint requests to Ann-Lii Cheng, M.D., Ph.D., Department of Internal Medicine and Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan S Rd, Taipei, Taiwan; e-mail: andrew@ha.mc.ntu.edu.tw

and Li-Tzong Chen, M.D., Ph.D., Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan; e-mail: leochen@nhri.org.tw

Content: 28 text pages, 1 table, 4 figures.
ABSTRACT

T(11;18)(q21;q21) is a specific marker for Helicobacter pylori (H pylori)-independent status of low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, there are currently no reliable markers to predict tumor response to H pylori eradication for cases without t(11;18)(q21;q21). Nuclear expression of BCL10 and NF-κB was recently found to be closely associated with H pylori-independent status of the high-grade counterpart of gastric MALT lymphoma, which usually lacks t(11;18)(q21;q21). This study examined whether these two markers can also predict H pylori-independent status of low-grade gastric MALT lymphomas without t(11;18)(q21;q21).

Sixty patients who underwent successful H pylori eradication for low-grade gastric MALT lymphomas were included. Forty-seven (78.3%) patients were negative for t(11;18)(q21;q21); among them, 36 (76.6%) were H pylori-dependent and 11 (23.4%) were H pylori-independent. Nuclear expression of BCL10 was significantly higher in H pylori-independent than in H pylori-dependent tumors (8 of 11 [72.7%] vs 3 of 36 [8.3%]; P < .001). Nuclear expression of NF-κB was also significantly higher in H pylori-independent than in H pylori-dependent tumors (7 of 11 [63.6%] vs 3 of 36 [8.3%]; P < .001). Further, nuclear translocation of BCL10 and NF-κB was observed in 12 of the 13 cases with t(11;18)(q21;q21); and all these 12 cases were H pylori-independent. In summary, nuclear expression of
BCL10 or NF-κB is predictive of *H pylori*-independent status of low-grade gastric MALT lymphoma with or without t(11;18)(q21;q21).
Introduction

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma represents the most common type of MALT lymphoma and is characterized by its close association with Helicobacter pylori (H pylori) infection. Eradication of H pylori by antibiotics cures approximately 70% of this tumor. Although t(11;18)(q21;q21) is one of the most important predictors of H pylori-independence in low-grade gastric MALT lymphomas, only 50% to 70% of H pylori-independent low-grade gastric MALT lymphomas harbor this genetic aberration. In other words, 30-50% of H pylori-independent low-grade gastric MALT lymphomas have no reliable markers to predict their H pylori-independent status. Therefore, identification of other easily detected molecular markers that can provide high sensitivity in predicting H pylori-independent status of low-grade gastric MALT lymphomas without t(11;18)(q21;q21) is mandatory.

Several genetic changes are implicated in the development of gastric MALT lymphoma. T(1;14)(p22;q32) is one of the most important genetic aberration, which juxtaposes the BCL10 gene of chromosome 1p to the immunoglobulin gene locus of chromosome 14q and results in strong expression of a truncated BCL10 protein in the nuclei and cytoplasm. However, the majority of MALT lymphomas with BCL10 nuclear localization do not have genetic aberrations of t(1;14)(p22;q32) or other
BCL10 gene mutations.9-12 Surprisingly, BCL10 nuclear expression was found to be more closely associated with the genetic aberration t(11;18)(q21;q21), which is a specific marker for *H pylori*-independence of low-grade gastric MALT lymphoma.13 In B lymphocyte, BCL10 is an intracellular protein that positively regulates lymphocyte proliferation by linking antigen receptor stimulation to activate NF-κB signaling.14,15 Moreover, the chimeric protein of t(11;18)(q21;q21) itself leads to constitutive NF-κB activity through self-oligomerization of the baculovirus IAP repeat (BIR) domain of the API2 molecule.16 As NF-κB is known to mediate cell survival and anti-apoptotic signals,17 it has been speculated that its upregulation may contribute to the malignant transformation of *H pylori*-independent growth of MALT lymphomas.

Recently, we demonstrated that a substantial portion of high-grade gastric MALT lymphomas remain *H pylori*-dependent and can be cured by *H pylori* eradication.18 We have also clarified that nuclear translocation of BCL10 or NF-κB is the pivotal molecular determinant of *H pylori*-independence in high-grade gastric MALT lymphoma and that co-expression of these two markers in the nuclei is frequent.19 Since t(11;18)(q21;q21) rarely occurs in high-grade gastric MALT lymphomas,20,21 it is reasonable to speculate that nuclear translocation of BCL10 and NF-κB may also be useful for predicting *H pylori*-independent status of those low-grade gastric MALT
lymphomas which lack t(11;18)(q21;q21).

In this study, we analyzed the genetic aberration of t(11;18)(q21;q21) and the expression patterns of BCL10 and NF-κB in 37 *H pylori*-dependent and 23 *H pylori*-independent low-grade gastric MALT lymphomas. We found that nuclear expression of these two markers is highly useful in predicting *H pylori*-independent status of low-grade gastric MALT lymphomas with or without t(11;18)(q21;q21).
Patients and methods

Patients, treatment, and evaluation of the tumors

Sixty patients who had participated in a prospective study of \( H\) pylori eradication for localized low-grade gastric MALT lymphomas and had subsequently had their gastric \( H\) pylori infection eradicated, as defined by negative results for biopsy urease test, histology, and bacterial culture, were included in this study. The diagnosis of low-grade gastric MALT lymphoma was made according to the histologic criteria described by Chan et al.\(^2^2\). The tumors were characterized by the presence of predominantly low-grade centrocyte-like cell infiltrates, the presence of lymphoepithelial lesions, the absence of confluent clusters or sheets of large cells resembling centroblasts or lymphoblasts, and the absence of predominance of high-grade lymphoma cells. The histopathologic characteristics of all tumor specimens were independently reviewed by two experienced hematopathologists. Staging was performed classified according to Musshoff’s modification of the Ann Arbor staging system.\(^2^3\)

At the beginning of the study, the \( H\) pylori eradication regimen consisted of amoxicillin 500 mg and metronidazole 250 mg qid with either bismuth subsalicylate 120 mg qid or omeprazole 20 mg bid for 4 weeks, but was changed to amoxicillin 500 mg qid, clarithromycin 500 mg bid, plus omeprazole 20 mg bid for 2 weeks after March.
Patients were scheduled to undergo first follow-up upper gastrointestinal endoscopic examination 4 to 6 weeks after completion of antimicrobial therapy, and follow-up was then repeated every 6 to 12 weeks until histologic evidence of remission was found. At each follow-up examination, four to six biopsy specimens were taken from the antrum and body of the stomach for the evaluation of \textit{H pylori} infection, and a minimum of six biopsy specimens were taken from each of the tumors and suspicious areas for histologic evaluation. Diagnosis of \textit{H pylori} infection was based on histologic examination, biopsy urease test, and bacterial culture. Tumor regression after eradication therapy was histologically evaluated according to the criteria of Wotherspoon et al.\textsuperscript{24} Tumors that resolved to Wotherspoon grade 2 or less after successful \textit{H pylori} eradication were considered \textit{H pylori}-dependent. Tumors that had objective evidence of progression any time during the follow-up or tumors that failed to show histologic regression 12 months after successful \textit{H pylori} eradication were considered \textit{H pylori}-independent.\textsuperscript{5}

The prospective clinical trial, the pathologic review and the genetic studies of archived tumor tissues were approved by the institutional ethics review board.

The prospective clinical trial, the pathologic review, and the genetic studies of archived tumor tissues were approved by the Institutional Review Board at National Taiwan University Hospital. Information consent was provided according to the
Declaration of Helsinki.

**Immunohistochemistry and confocal laser scanning microscopy**

Formalin-fixed, paraffin-embedded sections cut at a thickness of 4 µm were deparaffinized and rehydrated through xylenes and a graded alcohol series. After antigen retrieval by heat treatment in 0.1 M citrate buffer at pH 6.0, endogenous peroxidase activity was blocked by 3% H₂O₂. Briefly, slides were incubated for 30 minutes in 2.5% normal donkey serum or goat serum. The slides were then incubated overnight at 4°C either with polyclonal goat antihuman BCL10 (1:10; sc-9560; Santa Cruz Biotechnology, Santa Cruz, CA) or polyclonal rabbit antihuman RelA (p65; 1:100; sc-7151; Santa Cruz Biotechnology) and incubated with secondary antibodies (BCL10, donkey anti-goat immunoglobulin; RelA, goat anti-rabbit immunoglobulin; Santa Cruz Biotechnology) according to the manufacturer's instructions. Finally, antibody binding was detected by the avidin-biotin-peroxidase method. Reaction products were developed using 3’, 5’-diaminobenzidine (Dako, Glostrup, Denmark) as a substrate for peroxidase. Sections were counterstained with Mayer's hematoxylin. All of the washes were performed in phosphate-buffered saline (pH 7.4). Staining was considered positive for BCL10 or NF-κB when the protein was detected in more than 10% of tumor cells with nuclear staining.⁹,¹² Reactive spleen and lymph node tissue sections were used as controls.
For double-immunolabeling studies, fluorescein isothiocyanate-labeled donkey anti-goat immunoglobulin G (IgG) or rhodamine-labeled goat anti-rabbit IgG was incubated as a secondary antibody for 60 minutes at room temperature in the dark. The sections were further evaluated under a confocal laser scanning microscope (model TC-SP; Leica, Heidelberg, Germany) equipped with argon and argon-krypton laser sources.

**Multiplex reverse transcriptase polymerase chain reaction for the API2-MALT1 fusion transcript**

Total cellular RNA was extracted from formalin-fixed, paraffin-embedded tissues using an Ambion RNA isolation kit (AMS Biotechnology, Oxon, United Kingdom). Briefly, two to three pieces of 10-µm paraffin sections were deparaffinized in xylene. The tissue was digested with proteinase K (Roche Diagnostics, Mannheim, Germany) for 1 hour at 45°C and solubilized in a guanidinium-based buffer. RNA extracted from the paraffin-embedded tissues was analyzed for API2-MALT1 fusion using multiplex reverse transcriptase polymerase chain reaction (RT-PCR) as described previously.²¹ RNA was subjected to first-round multiplex one-tube RT-PCR, then to second-round nested multiplex PCRs (three parallel: second PCR-A, second PCR-B, and second PCR-C). The final PCR products were run on 3% agarose gel and stained with ethidium bromide. The band size ranged from 80 to 179 bp. PCR of
low-grade gastric MALT lymphoma samples known to possess API2-MALT1 fusion was used as a positive control. Beta-actin (190 bp) was amplified in parallel as an internal control. Where indicated, PCR products of the API2-MALT1 transcript were either directly sequenced or cloned into a vector (TOPO TA Cloning Kit; Invitrogen, Paisely, United Kingdom) and sequenced with vector primers using dye-labeled terminators (BigDye Terminators; Applied Biosystems, Foster City, CA) and analyzed on a DNA sequencer (model 310; Applied Biosystems).

Statistical analysis

Fisher's exact test and the $\chi^2$ test were used to analyze the correlation between the $H$ pylori-independent status of MALT lymphomas and the translocation t(11;18)(q21;q21) and expression patterns of BCL10 and NF-κB.
Results

Patients and tumor response to H pylori eradication

There were 37 patients with H pylori-dependent and 23 patients with H pylori-independent tumors. The clinicopathologic features of these patients and their tumor response to H pylori eradication are summarized in Table 1. The median duration between H pylori eradication and complete histologic remission was 2.6 months (range, 0.9 to 17 months), and 34 of 37 (91.9%) patients did so within 12 months of H pylori eradication. The median duration between H pylori eradication and commencement of other treatments for the 23 H pylori-independent patients was 13 months (range, 4-27 months). Eight patients, who had persistent or increasing epigastric discomforts and had endoscopically or pathologically documented progressive tumors during regular follow-up, were considered H pylori-independent and were started with salvage treatments within 12 months of H pylori eradication.

At a median follow-up of 69.2 months (range, 12 to 124 months), 35 patients who had achieved complete histologic remission after eradication of H pylori were alive and free of lymphoma. Two patients experienced histologic relapse.

API2-MALT1 fusion transcript of t(11;18)(q21;q21)

The API2-MALT1 fusion transcript for t(11;18)(q21;q21) was detected in 13 (21.7%) patients (Figure 1). The sequencing analysis of the RT-PCR products
confirmed the presence of API2-MALT1 fusion transcript in all 13 patients, and the characteristics of all API2-MALT1 fusion variants were in keeping with those reported previously.\textsuperscript{21}

**Correlation of nuclear expression of BCL10 and NF-κB with tumor response to**

*H pylori* eradication in low-grade gastric MALT lymphoma without t(11;18)(q21;q21)

Among the 47 patients without t(11;18)(q21;q21), the frequency of nuclear expression of BCL10 was significantly higher in *H pylori*-independent than in *H pylori*-dependent tumors (8 of 11 [72.7\%] vs 3 of 36 [8.3\%]; \(P < .001\)) (Table 1, Figure 2). The frequency of nuclear expression of NF-κB was also significantly higher in *H pylori*-independent tumors than in *H pylori*-dependent low-grade gastric MALT lymphomas (7 of 11 [63.6\%] vs 3 of 36 [8.3\%]; \(P < .001\)) (Table 1). Nuclear co-expression of these 2 markers was seen in four cases examined by confocal microscopy. The nuclear expression of BCL10 had a sensitivity of 72.7\% and a specificity of 91.7\% in predicting *H pylori*-independence of low-grade gastric MALT lymphomas without t(11;18)(q21;q21). The nuclear expression of NF-κB had a sensitivity of 63.6\% and a specificity of 91.7\% in predicting *H pylori*-independence of low-grade gastric MALT lymphomas without t(11;18)(q21;q21).
**H pylori eradication in low-grade gastric MALT lymphoma patients with t(11;18)(q21;q21)**

As expected, 12 (92.3%) of the 13 patients with t(11;18)(q21;q21) had *H pylori*-independent lymphoma. The MALT lymphoma of all these 12 patients had nuclear translocation of both BCL10 and NF-κB. It is noteworthy that the only tumor with the genetic aberration of t(11;18)(q21;q21) but a cytoplasmic location of BCL10 and NF-κB was *H pylori*-dependent.

**Correlation of nuclear expression of BCL10 and NF-κB with tumor response to H pylori eradication in all low-grade gastric MALT lymphoma patients**

As a single variable, the frequency of nuclear expression of BCL10 was significantly higher in *H pylori*-independent than *H pylori*-dependent tumors (20 of 23 [86.9%] vs 3 of 37 [8.1%]; *P* < .001). The frequency of nuclear expression of NF-κB was also significantly higher in *H pylori*-independent than *H pylori*-dependent tumors (19 of 23 [82.6%] vs 3 of 37 [8.1%]; *P* < .001). The sensitivity in predicting *H pylori*-independence of low-grade gastric MALT lymphomas was 86.9% for nuclear expression of BCL10 and 82.6% for nuclear expression of NF-κB. The specificity in predicting *H pylori*-independence of low-grade gastric MALT lymphomas was 91.9% for nuclear expression of either BCL10 or NF-κB (Table 1).
Discussion

In this study, we demonstrated that nuclear expression of BCL10 and nuclear expression of NF-κB are two highly useful markers for predicting the *H pylori*-independent status of low-grade gastric MALT lymphomas with or without t(11;18)(q21;q21).

T (11;18)(q21;21) results in the expression of a chimeric protein with the amino terminal of the API2 fusing the carboxyl terminal MALT1, and is closely associated with *H pylori*-independent state of low-grade gastric MALT lymphoma. In a large retrospective study, t (11;18)(q21;21) was detected in 60% of stage IE *H pylori*-independent low-grade gastric MALT lymphomas. These results are in line with our observation that t (11;18)(q21;21) was found in only half of *H pylori*-independent, early-stage low-grade gastric MALT lymphomas. For the other half of *H pylori*-independent tumors, other predictive markers should be pursued.

In our previous studies, we showed that nuclear translocation and co-expression of BCL10 and NF-κB was closely associated with the *H pylori*-independent status of high-grade gastric MALT lymphomas, which usually lack t(11;18)(q21;q21). In this study, we extended this finding to include low-grade gastric MALT lymphoma lacking t(11;18)(q21;q21). That a proportion of low-grade MALT lymphomas lacking t(11;18)(q21;q21) express nuclear BCL10 has also been observed by several
other groups of investigators, although the relationship with *H pylori*-independence was not described.\textsuperscript{26,27} BCL10 contains a caspase recruitment (CARD) domain, and a C-terminal serine- and threonine-rich domain.\textsuperscript{7,8} Recent evidence indicates that upregulation of B-cell antigen receptor signaling triggers the activation of protein kinase C β and thereby results in phosphorylation of CARMA1 (also known as CARD11 or BIMP1), leading to BCL10 oligomerization.\textsuperscript{14,28,29} BCL10 then activates NF-κB by MALT1 and ubiquitin-conjugating enzyme-dependent IκB kinase ubiquitination.\textsuperscript{30} As NF-κB is activated, it translocates to the nucleus and results in the production of cytokines and growth factors that are important for cellular activation, proliferation and survival of B-cells.\textsuperscript{17} In the present study, nuclear expression of NF-κB was closely associated with the aberrant nuclear expression of BCL10 in *H pylori*-independent low-grade gastric MALT lymphoma. This finding is in line with our previous study which reported that nuclear translocation of NF-κB was highly predictive of *H pylori*-independent status in high-grade gastric MALT lymphoma.\textsuperscript{19} Additional investigation of the molecular interaction and biologic consequences of nuclear translocation of BCL10 and NF-κB in gastric MALT lymphoma is needed.

It is noteworthy that nuclear translocation of BCL10 and NF-κB was observed in all but one case with t(11;18)(q21;q21) in this series, and this exception occurred in a
patient who had a rare *H pylori*-dependent t(11;18)(q21;q21)-positive tumor. This finding implies that nuclear translocation of BCL10 and NF-κB may even be more specific than t(11;18)(q21;q21) in predicting *H pylori*-independence for gastric MALT lymphoma. Interestingly, the fusion transcript of this patient comprised the amino terminal API2 with 3 intact BIR domains and the carboxy terminal MALT1 region containing an intact caspase-like domain but no Ig-like domain (data not shown). Indeed, the fusion products with an intact Ig-like domain have been shown to be more potent activators of NF-κB than those without an Ig-like domain.\(^\text{16, 29}\) Whether the patterns of fusion transcripts of t(11;18)(q21;q21) may contribute to nuclear translocation of NF-κB or BCL10 and thereby affect *H pylori*-independence transformation of the tumor remains to be clarified.

This study did not examine other rare genetic aberrations that may relate to nuclear BCL10 expression. However, several recent studies detected t(1;14)(p22;q32) in less than 5% of low-grade MALT lymphomas.\(^\text{9,31}\) Indeed, 30-40% of gastric MALT lymphomas lacking both t(11;18)(q21;q21) and t(1;14)(p22;q32) showed a moderate degree of nuclear expression of BCL10.\(^\text{31}\) Moreover, a recent study of 71 cases of gastric MALT lymphoma found that none harbored t(1;14)(p22;32),\(^\text{32}\) suggesting that the latter genetic aberration is so rare that it may not be useful as a predictor. Since immunohistochemical staining for
detection of BCL10 or NF-κB nuclear expression is not only specific and sensitive in predicting *H pylori*-independent status but also much more feasible for the daily practice of general pathology laboratories, it is an invaluable method to help select the best first-line treatment for patients with low-grade gastric MALT lymphoma.
References


### Table 1. Clinicopathologic features of patients and their tumor response to *H. pylori* eradication

<table>
<thead>
<tr>
<th></th>
<th>Complete remission (%)</th>
<th>No remission (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>37 (61.6%)</td>
<td>23 (38.4%)</td>
<td>NS</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>57 (35-84)</td>
<td>56 (36-74)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15 (40.5%)</td>
<td>11 (47.8%)</td>
<td>NS</td>
</tr>
<tr>
<td>Female</td>
<td>22 (59.5%)</td>
<td>12 (52.2%)</td>
<td></td>
</tr>
<tr>
<td>Stages by EUS and CT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucosa/submucosa</td>
<td>26 (70.3%)</td>
<td>16 (69.6%)</td>
<td>NS</td>
</tr>
<tr>
<td>Muscularis propria/serosa</td>
<td>11 (29.7%)</td>
<td>7 (30.4%)</td>
<td></td>
</tr>
<tr>
<td>API2-MALT1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>1 (2.7%)</td>
<td>12 (52.2%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Negative</td>
<td>36 (97.3%)</td>
<td>11 (47.8%)</td>
<td></td>
</tr>
<tr>
<td>BCL10 expression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytoplasmic</td>
<td>34 (91.9%)</td>
<td>3 (13.1%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Nuclear/cytoplasmic</td>
<td>3 (8.1%)</td>
<td>20 (86.9%)</td>
<td></td>
</tr>
<tr>
<td>NF-κB expression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytoplasmic</td>
<td>34 (91.9%)</td>
<td>4 (17.4%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Nuclear/cytoplasmic</td>
<td>3 (8.1%)</td>
<td>19 (82.6%)</td>
<td></td>
</tr>
</tbody>
</table>

NS: not significant.
Figure Legends

Figure 1. Detection of t(11;18)(q21;q21) by multiplex RT-PCR of the API2-MALT1 fusion transcript. (A) Second PCR-A; (B) Second PCR-B; (C) Second PCR-C; lane N, negative control (normal lymph node); lanes 1 to 12, *H pylori*-independent MALT lymphomas (positive); lanes 13, *H pylori*-dependent MALT lymphoma (positive); lanes 14 to 16, *H pylori*-dependent MALT lymphomas (negative). Beta-actin mRNA is amplified in all cases.

Figure 2. BCL10 and NF-κB protein expression in low-grade gastric MALT lymphomas with and without t(11;18)(q21;q21). (A, B, C) BCL10; (D, E, F) NF-κB; (A, D) nuclear BCL10 and NF-κB expression in *H pylori*-independent patients with t(11;18); (B, E) nuclear BCL10 and NF-κB expression in *H pylori*-independent patients without t(11;18); (C, F) cytoplasmic BCL10 expression and NF-κB expression in *H pylori*-dependent patients. Original magnification x 400.
Figure 3. Scheme of the relationship between *H pylori*-independence and API2-MALT1 fusion transcript and protein expression of BCL10 and NF-κB. *n*: the number of cases in individual subgroups; *N*: nuclear expression; C: cytoplasmic expression.
Figure 4. Correlation between *H pylori*-independence and API2-MALT1 fusion transcript and nuclear expression of BCL10 and NF-κB. The number of cases in individual subgroups is indicated at the top of the corresponding histogram.
Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21)